Health|Science
US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised
June 24, 2024Your subscription includes
Unlimited Access to All Content from
The Los Angeles Post
An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised
June 24, 2024